Rznomics
476830KOSDAQ🇰🇷Healthcare · Biotechnology
Last updated: 6m ago
52-Week Range
Company Overview
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblas
🤖 AI Stock Analysis
📊 Valuation: With a PBR of 127.38, the company's current market value appears significantly overvalued relative to its book value.
💰 Profitability: Profitability is very low, with net profit margin and operating profit margin both at 0.0%, indicating no earnings generation.
📈 Growth: Growth cannot be assessed based solely on the provided metrics.
💵 Dividend: The company has a dividend payout ratio of 0.0%, meaning no dividends are distributed.
💬 Summary: Algenomics appears to have low investment attractiveness due to its high valuation and poor profitability. Further analysis of growth potential is recommended.
AI-generated reference material. Not investment advice.